Gastrointestinal Stromal Tumors, Somatic Mutations and Candidate Genetic Risk Variants

被引:24
|
作者
O'Brien, Katie M. [1 ]
Orlow, Irene [2 ]
Antonescu, Cristina R. [3 ]
Ballman, Karla [4 ]
McCall, Linda [5 ]
DeMatteo, Ronald [6 ]
Engel, Lawrence S. [1 ]
机构
[1] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27515 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
[4] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA
[5] Amer Coll Surg, Oncol Grp, Durham, NC USA
[6] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA
来源
PLOS ONE | 2013年 / 8卷 / 04期
关键词
S-TRANSFERASE M1; CYP1B1 LEU432VAL POLYMORPHISM; COLORECTAL-CANCER RISK; SOFT-TISSUE SARCOMA; SINGLE NUCLEOTIDE POLYMORPHISMS; GERMLINE MUTATION; BLADDER-CANCER; DNA-REPAIR; C-KIT; ASSOCIATION;
D O I
10.1371/journal.pone.0062119
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Gastrointestinal stromal tumors (GISTs) are rare but treatable soft tissue sarcomas. Nearly all GISTs have somatic mutations in either the KIT or PDGFRA gene, but there are no known inherited genetic risk factors. We assessed the relationship between KIT/PDGFRA mutations and select deletions or single nucleotide polymorphisms (SNPs) in 279 participants from a clinical trial of adjuvant imatinib mesylate. Given previous evidence that certain susceptibility loci and carcinogens are associated with characteristic mutations, or "signatures'' in other cancers, we hypothesized that the characteristic somatic mutations in the KIT and PDGFRA genes in GIST tumors may similarly be mutational signatures that are causally linked to specific mutagens or susceptibility loci. As previous epidemiologic studies suggest environmental risk factors such as dioxin and radiation exposure may be linked to sarcomas, we chose 208 variants in 39 candidate genes related to DNA repair and dioxin metabolism or response. We calculated adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the association between each variant and 7 categories of tumor mutation using logistic regression. We also evaluated gene-level effects using the sequence kernel association test (SKAT). Although none of the association p-values were statistically significant after adjustment for multiple comparisons, SNPs in CYP1B1 were strongly associated with KIT exon 11 codon 557-8 deletions (OR = 1.9, 95% CI: 1.3-2.9 for rs2855658 and OR = 1.8, 95% CI: 1.2-2.7 for rs1056836) and wild type GISTs (OR = 2.7, 95% CI: 1.5-4.8 for rs1800440 and OR = 0.5, 95% CI: 0.3-0.9 for rs1056836). CYP1B1 was also associated with these mutations categories in the SKAT analysis (p = 0.002 and p = 0.003, respectively). Other potential risk variants included GSTM1, RAD23B and ERCC2. This preliminary analysis of inherited genetic risk factors for GIST offers some clues about the disease's genetic origins and provides a starting point for future candidate gene or gene-environment research.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Kinase Mutations and Efficacy of Imatinib in Korean Patients with Advanced Gastrointestinal Stromal Tumors
    Kim, Tae Won
    Ryu, Min-Hee
    Lee, Heungnam
    Sym, Sun Jin
    Lee, Jae-Lyun
    Chang, Heung Moon
    Park, Young Suk
    Lee, Kyung Hee
    Kang, Won Ki
    Shin, Dong Bok
    Bang, Yung-Jue
    Lee, Jung Shin
    Kang, Yoon-Koo
    ONCOLOGIST, 2009, 14 (05) : 540 - 547
  • [32] Update on Molecular Genetics of Gastrointestinal Stromal Tumors
    Brcic, Iva
    Argyropoulos, Alexandra
    Liegl-Atzwanger, Bernadette
    DIAGNOSTICS, 2021, 11 (02)
  • [33] Gastrointestinal Stromal Tumors-A Mini Review
    Gheorghe, Gina
    Bacalbasa, Nicolae
    Ceobanu, Gabriela
    Ilie, Madalina
    Enache, Valentin
    Constantinescu, Gabriel
    Bungau, Simona
    Diaconu, Camelia Cristina
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (08):
  • [34] Targeting gastrointestinal stromal tumors: the role of regorafenib
    Schroeder, Brett
    Li, Zula
    Cranmer, Lee D.
    Jones, Robin L.
    Pollack, Seth M.
    ONCOTARGETS AND THERAPY, 2016, 9 : 3009 - 3016
  • [35] Management of gastrointestinal stromal tumors
    Rajendra, Rajeev
    Pollack, Seth M.
    Jones, Robin L.
    FUTURE ONCOLOGY, 2013, 9 (02) : 193 - 206
  • [36] Management of Gastrointestinal Stromal Tumors
    Keung, Emily Z.
    Raut, Chandrajit P.
    SURGICAL CLINICS OF NORTH AMERICA, 2017, 97 (02) : 437 - +
  • [37] Resistance in gastrointestinal stromal tumors
    Seeber, Andreas
    Perathoner, Alexander
    Kocher, Florian
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2019, 12 (02) : 140 - 143
  • [38] The immunotherapy in gastrointestinal stromal tumors
    Yu, Guilin
    Liu, Ruibin
    Li, Jiayao
    Zhao, Guohua
    Wang, Yue
    HELIYON, 2024, 10 (13)
  • [39] Gastrointestinal Stromal Tumors: A Review
    Asija, Aakanksha Prasad
    Mejia, Alex V.
    Prestipino, Anthony
    Pillai, Madhavan V.
    AMERICAN JOURNAL OF THERAPEUTICS, 2016, 23 (02) : E550 - E557
  • [40] Gastrointestinal stromal tumors of the stomach
    Wardelmann, E.
    Hohenberger, P.
    Reichardt, P.
    Merkelbach-Bruse, S.
    Schildhaus, H. -U.
    Buettner, R.
    PATHOLOGE, 2010, 31 (03): : 195 - 198